A Human Model of Epithelial to Mesenchymal Transition to Monitor Drug Efficacy in Hepatocellular Carcinoma Progression
- 1 May 2011
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 10 (5), 850-860
- https://doi.org/10.1158/1535-7163.mct-10-0917
Abstract
The epithelial to mesenchymal transition (EMT) of malignant hepatocytes is a crucial event in hepatocellular carcinoma (HCC) progression and recurrence. We aimed to establish a human model of EMT to examine drug efficacy and specificity in HCC progression. Human HCC cell populations were characterized by immunofluorescence analysis, migration and invasion assays, array comparative genomic hybridization, whole-genome expression profiling, and promoter methylation. Therapeutic agents clinically used against HCC were examined for efficacy by determination of IC50 values. We show that liver cancer cell lines exhibited either an epithelial or mesenchymal phenotype of which the latter showed strong migratory and invasive abilities in vitro. The common cellular origin of both cell types indicated that mesenchymal HCC cells have been derived from epithelial hepatocytes through EMT in the HCC patient. Drug exposure of mesenchymal HCC cells showed higher resistance to the targeted therapeutic agents sorafenib and erlotinib as compared to epithelial HCC cells, which were slightly more resistant to cytostatic drugs. Most remarkably, combined treatment with doxorubicin and sorafenib caused increased susceptibility of both HCC cell types resulting in enhanced drug efficacy. Taken together, this EMT model of human HCC allows the identification of molecular mechanisms and the assessment of therapeutic drug efficacy during liver cancer progression in preclinical studies. Mol Cancer Ther; 10(5); 850–60. ©2011 AACR.Other Versions
This publication has 26 references indexed in Scilit:
- Epithelial-Mesenchymal Transitions in Development and DiseaseCell, 2009
- The epithelial-mesenchymal transition: Fact or fiction in cancer?Journal of Hepatology, 2009
- Epithelial–mesenchymal transition in hepatocellular carcinomaFuture Oncology, 2009
- Hepatic tumor–stroma crosstalk guides epithelial to mesenchymal transition at the tumor edgeOncogene, 2009
- Comprehensive analysis of the independent effect of twist and snail in promoting metastasis of hepatocellular carcinomaJournal of Hepatology, 2009
- SorafenibDrugs, 2009
- Sorafenib in Advanced Hepatocellular CarcinomaThe New England Journal of Medicine, 2008
- New cellular tools reveal complex epithelial–mesenchymal interactions in hepatocarcinogenesisBritish Journal of Cancer, 2008
- Transforming growth factor-β gene expression signature in mouse hepatocytes predicts clinical outcome in human cancerJournal of Hepatology, 2008
- Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survivalJournal of Hepatology, 2003